Immune resistance in pancreatic ductal adenocarcinoma
Published 1 May 2026
Pancreatic ductal adenocarcinoma (PDAC) ranks among the deadliest malignancies, due in large part to a highly immunosuppressive tumour microenvironment. Although approximately 30% of PDAC tumours express PD L1, immune ...Continue reading




